## **Catherine Guette**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8033309/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lymphoid Organ Proteomes Identify Therapeutic Efficacy Biomarkers Following the Intracavitary Administration of Curcumin in a Highly Invasive Rat Model of Peritoneal Mesothelioma. International Journal of Molecular Sciences, 2021, 22, 8566.	1.8	5
2	tRNA biogenesis and specific aminoacyl-tRNA synthetases regulate senescence stability under the control of mTOR. PLoS Genetics, 2021, 17, e1009953.	1.5	11
3	Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapyâ€ʻinduced senescence escape. International Journal of Oncology, 2021, 60, .	1.4	8
4	Cross-Species Proteomics Identifies CAPG and SBP1 as Crucial Invasiveness Biomarkers in Rat and Human Malignant Mesothelioma. Cancers, 2020, 12, 2430.	1.7	9
5	RE: Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). Journal of the National Cancer Institute, 2020, 112, 863-864.	3.0	1
6	S100A4 Is a Biomarker of Tumorigenesis, EMT, Invasion, and Colonization of Host Organs in Experimental Malignant Mesothelioma. Cancers, 2020, 12, 939.	1.7	17
7	Biomarkers of tumor invasiveness in proteomics (Review). International Journal of Oncology, 2020, 57, 409-432.	1.4	18
8	Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity. Cell Cycle, 2019, 18, 2385-2397.	1.3	61
9	OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATHâ€Based Proteomic Approach. Proteomics, 2019, 19, e1800446.	1.3	17
10	Proteomics Approaches to Define Senescence Heterogeneity and Chemotherapy Response. Proteomics, 2019, 19, 1800447.	1.3	6
11	iTRAQâ€Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Tripleâ€Negative Breast Cancer Tumors. Proteomics, 2019, 19, 1800484.	1.3	14
12	Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment. Cell Death and Disease, 2019, 10, 199.	2.7	62
13	Regulation of senescence escape by the cdk4–EZH2–AP2M1 pathway in response to chemotherapy. Cell Death and Disease, 2018, 9, 199.	2.7	47
14	Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma. Oncotarget, 2018, 9, 16311-16329.	0.8	9
15	BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nature Communications, 2017, 8, 1123.	5.8	43
16	Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis. Oncotarget, 2015, 6, 43342-43362.	0.8	27
17	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Research, 2015, 17, 43.	2.2	248
18	Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples. Molecular and Cellular Proteomics, 2015, 14, 2936-2946.	2.5	61

CATHERINE GUETTE

#	Article	IF	CITATIONS
19	Olfactomedinâ€4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers. Proteomics - Clinical Applications, 2015, 9, 58-63.	0.8	18
20	lrinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1. Oncotarget, 2015, 6, 409-426.	0.8	42
21	Abstract P2-04-07: Gene-expression molecular subtyping of immunohistochemistry-typed triple-negative breast cancer tumours. , 2015, , .		Ο
22	Glioblastomaâ€associated stromal cells ( <scp>GASCs</scp> ) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties. Journal of Pathology, 2014, 233, 74-88.	2.1	67
23	Twoâ€ <b>s</b> tep OFFGEL approach for effective peptide separation compatible with iTRAQ labeling. Proteomics, 2013, 13, 3261-3266.	1.3	2
24	How should we define STAT3 as an oncogene and as a potential target for therapy?. Jak-stat, 2013, 2, e24716.	2.2	43
25	Comparison of Spheroids Formed by Rat Glioma Stem Cells and Neural Stem Cells Reveals Differences in Glucose Metabolism and Promising Therapeutic Applications. Journal of Biological Chemistry, 2012, 287, 33664-33674.	1.6	55
26	Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: A multicentric 2004 national PHRC study. International Journal of Oncology, 2012, 41, 92-104.	1.4	8
27	Intestinal cell targeting of a stable recombinant Cu–Zn SOD from Cucumis melo fused to a gliadin peptide. Journal of Biotechnology, 2012, 159, 99-107.	1.9	4
28	A Quantitative Proteomic Approach of the Different Stages of Colorectal Cancer Establishes OLFM4 as a New Nonmetastatic Tumor Marker. Molecular and Cellular Proteomics, 2011, 10, M111.009712.	2.5	103
29	OFFGEL-Isoelectric Focusing Fractionation for the Analysis of Complex Proteome. Neuromethods, 2011, , 145-158.	0.2	2
30	A Proteomic Approach for Plasma Biomarker Discovery with iTRAQ Labelling and OFFGEL Fractionation. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-8.	3.0	65
31	Differential Protein Modulation in Midguts of Aedes aegypti Infected with Chikungunya and Dengue 2 Viruses. PLoS ONE, 2010, 5, e13149.	1.1	130
32	Affinity capture using chimeric membrane proteins bound to magnetic beads for rapid ligand screening by matrixâ€assisted laser desorption/ionization timeâ€ofâ€flight mass spectrometry. Rapid Communications in Mass Spectrometry, 2009, 23, 745-755.	0.7	6
33	Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation. Proteome Science, 2008, 6, 27.	0.7	60
34	Kalanchosine Dimalate, an Anti-inflammatory Salt fromKalanchoebrasiliensis. Journal of Natural Products, 2006, 69, 815-818.	1.5	23
35	Peptide profiling by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry of the Lasiodora parahybana tarantula venom gland. Toxicon, 2006, 47, 640-649.	0.8	31
36	The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata. Phytochemistry, 2006, 67, 2071-2077.	1.4	139

CATHERINE GUETTE

#	Article	IF	CITATIONS
37	Solution structure of PcFK1, a spider peptide active against Plasmodium falciparum. Protein Science, 2006, 15, 628-634.	3.1	24
38	Quercitrin: An Antileishmanial Flavonoid Glycoside fromKalanchoe pinnata. Planta Medica, 2006, 72, 81-83.	0.7	118
39	First report in a river in France of the benthic cyanobacterium Phormidium favosum producing anatoxin-a associated with dog neurotoxicosis. Toxicon, 2005, 45, 919-928.	0.8	276
40	Nanospray analysis of the venom of the tarantulaTheraphosa leblondi: a powerful method for direct venom mass fingerprinting and toxin sequencing. Rapid Communications in Mass Spectrometry, 2004, 18, 1024-1032.	0.7	24
41	An unusual cleavage reaction of a peptide observed during dithiotreitol and tris(2-carboxyethyl)phosphine reduction: application to sequencing of HpTx2 spider toxin using nanospray tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2004, 18, 1317-1323.	0.7	4
42	Isolation and characterization of Psalmopeotoxin I and II: two novel antimalarial peptides from the venom of the tarantulaPsalmopoeus cambridgei. FEBS Letters, 2004, 572, 109-117.	1.3	58
43	Modulation of Kv4.2 channels by a peptide isolated from the venom of the giant bird-eating tarantula Theraphosa leblondi. Toxicon, 2004, 43, 923-932.	0.8	34
44	Isolation and structure of cyclosenegalins A and B, novel cyclopeptides from the seeds of Annona senegalensis. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 2712-2718.	1.3	10
45	Bromation régiosélective en série aromatique. II. Approche théorique du mécanisme de la substitution électrophile par l'ion tribromure Br3â^. Canadian Journal of Chemistry, 1990, 68, 464-470.	0.6	7
46	Bromation régiosélective en série aromatique. l: Monobromation en position para de phénols et d'aminés aromatiques par le tribromure de tétrabutylammonium. Canadian Journal of Chemistry, 1989, 67, 2061-2066.	0.6	45
47	Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies. Frontiers in Pharmacology, 0, 13, .	1.6	3